A charity survey has highlighted an “urgent need” for earlier diagnosis of kidney cancer, revealing that, in 51 percent of cases, the disease is detected from scans relating to other health conditions.
Santhera's attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has put forward seven new medicines for approval in the region, including new treatment options for haemophilia A, diabetes, and a very rare genetic disorder.
Alzheimer’s disease research has taken another hit with the termination of a Phase III study assessing the effect of diabetes drug pioglitazone on mild cognitive impairment (MCI) in patients with the condition.
Final guidelines have now been published endorsing NHS use of Novartis’ Zykadia as a first line of attack for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), offering patients a new treatment option.
UK charity Parkinson’s UK is handing over more than $1 million in funding to US biotech company Neurolixis, to help fuel development of a novel, experimental therapy for patients with Parkinson’s disease.